Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SON 1010

Next Previous
Drug Profile

SON 1010

Alternative Names: IL12-FHAB; SON-1010

Latest Information Update: 28 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sonnet Biotherapeutics
  • Developer Sonnet BioTherapeutics Holdings, Inc
  • Class Antineoplastics; Immunoglobulin fragments; Immunoglobulin Fv fragments; Immunotherapies; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Interleukin 12 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Ovarian cancer; Solid tumours

Most Recent Events

  • 28 May 2025 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease) in USA (SC)
  • 28 May 2025 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Monotherapy) in USA (SC)
  • 04 Apr 2025 Sonnet Biotherapeutics receives positive feedback from a formal evaluation by the Safety Review Committee (SRC) for the SB221 study in Ovarian cancer and Solid tumours

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top